Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599489 | 0.89 | MAPK14 (0.74) | MAPK14SCN9A | |
| SCHEMBL599346 | 0.88 | MAPK14 (0.52) | MAPK14SCN9A | |
| SCHEMBL600705 | 0.85 | MAPK14 (0.73) | MAPK14SCN9A | |
| SCHEMBL2671812 | 0.83 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL601151 | 0.77 | MAPK14 (0.48) | MAPK14SCN9A | |
| SCHEMBL599677 | 0.76 | MAPK14 (0.54) | MAPK14SCN9A | |
| SCHEMBL2671638 | 0.75 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL600394 | 0.75 | MAPK14 (0.54) | MAPK14SCN9A | |
| SCHEMBL599512 | 0.74 | MAPK14 (0.48) | MAPK14SCN9A | |
| SCHEMBL601105 | 0.74 | MAPK14 (0.51) | MAPK14SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | MAPK1, MAPK4, MAPK12 | MAPK14 26/4885SCN9A 4288/4885SPR 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.